A股異動 | 獲券商看好天康生物大漲8.7% 前9月淨利同比增16.35%
格隆匯10月29日丨天康生物(002100.SZ)繼昨日漲停後,於今日至現價12.99元再度上漲8.7%,盤中最高見13.08元刷年內最高價,最新總市值132億,換手率8.5%。公司此前公告稱,前三季度實現營業收入51.80億元,同比增長39.59%;歸屬於上市公司股東的淨利潤3.02億元,同比增長16.35%;第三季度實現歸屬於上市公司股東的淨利潤2.22億元,同比增長46.57%。太平洋證券指,公司目前2/3產能分佈在新疆、甘肅等西北地區,防疫優勢顯著,產能保留較為完整;豬價上漲推動三季度盈利向好,四季度業績將持續增長。預計公司2019至2021年歸母淨利潤分別為6.55、20.97、23.79億元,給予2020年目標價21.72元,給予買入評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.